味の素株式会社とForge Biologics社の協働による遺伝子治療薬生産性向上

This document discusses the development of a culture supplement for gene therapy drugs by Ajinomoto Co., Inc. in collaboration with Forge Biologics. This supplement has been proven to enhance the productivity of viral vectors by up to twice the conventional levels, which is expected to improve the productivity of the gene therapy CDMO business. Gene therapy is gaining attention as a new treatment for difficult-to-treat diseases, with significant market growth anticipated. Ajinomoto has been involved in the biopharmaceutical culture medium business for over 30 years, and the development of this supplement is a continuation of that effort. General sales of the supplement are also being considered, with expectations for business expansion.